Agendia's MammaPrint Is First IVDMIA to Win FDA OK; Will New Imprimatur Be Advantageous?

Genomic Health, whose Oncotype Dx test was an early model for IVDMIAs, said the clearance of Agendia’s MammaPrint test does not necessarily guarantee it will be adopted by the market.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register quickly here.